Paper22754591
Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer.
Leung L and 2 others. Ther Adv Med Oncol, 2012. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. Papers, record 22754591. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22754591
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19917871 | American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19917871 | PubMed |
| 2 | 19494788 | Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. | J Thorac Oncol | 2009 | https://conductscience.org/library/papers/19494788 | PubMed |
| 3 | 17167137 | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. | N Engl J Med | 2006 | https://conductscience.org/library/papers/17167137 | PubMed |
| 4 | 14701780 | Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. | J Clin Oncol | 2004 | https://conductscience.org/library/papers/14701780 | PubMed |
| 5 | 17878479 | Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17878479 | PubMed |
| 6 | 16800963 | Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. | Clin Lung Cancer | 2006 | https://conductscience.org/library/papers/16800963 | PubMed |
| 7 | 20978446 | Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. | J Thorac Oncol | 2010 | https://conductscience.org/library/papers/20978446 | PubMed |
| 8 | 17671148 | Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17671148 | PubMed |
| 9 | 22547605 | Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22547605 | PubMed |
| 10 | 15118073 | Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15118073 | PubMed |
| 11 | 18678835 | Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18678835 | PubMed |
| 12 | 19410716 | Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. | Lancet | 2009 | https://conductscience.org/library/papers/19410716 | PubMed |
| 13 | 19692680 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19692680 | PubMed |
| 14 | 20100966 | Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20100966 | PubMed |
| 15 | 16890793 | Epidermal growth factor receptor targeting in cancer. | Semin Oncol | 2006 | https://conductscience.org/library/papers/16890793 | PubMed |
| 16 | 17442998 | Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17442998 | PubMed |
| 17 | 20573926 | Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20573926 | PubMed |
| 18 | 11784875 | Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. | N Engl J Med | 2002 | https://conductscience.org/library/papers/11784875 | PubMed |
| 19 | 19658185 | Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. | Cancer | 2009 | https://conductscience.org/library/papers/19658185 | PubMed |
| 20 | 16377102 | Epidermal growth factor receptor (EGFR) signaling in cancer. | Gene | 2006 | https://conductscience.org/library/papers/16377102 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42488708 | Safety and Efficacy of Aumolertinib as First-Line Treatment in EGFR-Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Phase II Study (ARISE Study). | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42488708 | PubMed |
| 41413930 | Drug-drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitors. | Expert Rev Clin Pharmacol | 2025 | https://conductscience.org/library/papers/41413930 | PubMed |
| 39991842 | Investigation of bioavailability and anti-pancreatic cancer efficacy of a self-nanoemulsifying erlotinib delivery system. | Ther Deliv | 2025 | https://conductscience.org/library/papers/39991842 | PubMed |
| 34572386 | Role of Calcium Homeostasis in Modulating EMT in Cancer. | Biomedicines | 2021 | https://conductscience.org/library/papers/34572386 | PubMed |
| 34090412 | EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation. | BMC Pulm Med | 2021 | https://conductscience.org/library/papers/34090412 | PubMed |
| 33262410 | Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer. | Sci Rep | 2020 | https://conductscience.org/library/papers/33262410 | PubMed |
| 32973931 | EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer. | Ther Adv Med Oncol | 2020 | https://conductscience.org/library/papers/32973931 | PubMed |
| 31572008 | Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study. | Cancer Manag Res | 2019 | https://conductscience.org/library/papers/31572008 | PubMed |
| 30171075 | RNF144A sustains EGFR signaling to promote EGF-dependent cell proliferation. | J Biol Chem | 2018 | https://conductscience.org/library/papers/30171075 | PubMed |
| 29536182 | Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer. | Pharm Res | 2018 | https://conductscience.org/library/papers/29536182 | PubMed |
| 26885448 | Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC). | Am J Cancer Res | 2015 | https://conductscience.org/library/papers/26885448 | PubMed |
| 26768483 | Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung. | Oncologist | 2016 | https://conductscience.org/library/papers/26768483 | PubMed |
| 25538894 | EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression. | Front Oncol | 2014 | https://conductscience.org/library/papers/25538894 | PubMed |
| 25502402 | Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles. | Sci Rep | 2014 | https://conductscience.org/library/papers/25502402 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22754591
GET https://conductscience.org/api/papers/v1/22754591/references?page=2